235 related articles for article (PubMed ID: 25083132)
1. Linagliptin use in older individuals with type 2 diabetes.
Pratley RE
Clin Interv Aging; 2014; 9():1109-14. PubMed ID: 25083132
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T; Pfützner A
Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.
von Websky K; Reichetzeder C; Hocher B
Vasc Health Risk Manag; 2013; 9():681-94. PubMed ID: 24204157
[TBL] [Abstract][Full Text] [Related]
5. Review of linagliptin for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Setter SM
Clin Ther; 2012 May; 34(5):993-1005. PubMed ID: 22440191
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
[TBL] [Abstract][Full Text] [Related]
8. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
9. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ
Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125
[TBL] [Abstract][Full Text] [Related]
10. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
McGill JB; Barnett AH; Lewin AJ; Patel S; Neubacher D; von Eynatten M; Woerle HJ
Diab Vasc Dis Res; 2014 Jan; 11(1):34-40. PubMed ID: 24169807
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
McKeage K
Drugs; 2014 Oct; 74(16):1927-1946. PubMed ID: 25297911
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Deeks ED
Drugs; 2012 Sep; 72(13):1793-824. PubMed ID: 22913735
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Grunberger G
Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Scheen AJ
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
[TBL] [Abstract][Full Text] [Related]
17. Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
Christensen M; Knop FK
Nat Rev Endocrinol; 2012 Oct; 8(10):576-8. PubMed ID: 22926098
[No Abstract] [Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
20. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
